Predictive Oncology Q4 2025 Earnings Report

Predictive Oncology EPS Results

• Actual EPS: $122.75
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Predictive Oncology Revenue Results

• Actual Revenue: $0.01 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Predictive Oncology Announcement Details

• Quarter: Q4 2025
• Date: 3/31/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Predictive Oncology (NASDAQ:AGPU) (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts. Predictive Oncology offers services and tools designed to help biopharmaceutical companies and research organizations evaluate therapeutic candidates and develop companion diagnostic strategies, leveraging a mix of experimental assays and data-driven analysis to generate actionable insights for oncology programs.

As a publicly traded company, Predictive Oncology works with commercial and research partners in the life sciences ecosystem. Publicly available, detailed historical background and current leadership information were limited at the time of this summary; readers seeking executive biographies, recent corporate developments or a full corporate history should consult the company’s regulatory filings and investor relations materials for the most current and authoritative information.